Shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) have received an average recommendation of “Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $21.57.
A number of equities research analysts recently issued reports on CLBT shares. JPMorgan Chase & Co. upped their target price on Cellebrite DI from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday, December 16th. Craig Hallum increased their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Needham & Company LLC lifted their price objective on Cellebrite DI from $21.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, January 22nd.
Check Out Our Latest Stock Report on Cellebrite DI
Cellebrite DI Stock Up 0.8 %
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.05. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The company had revenue of $106.90 million for the quarter, compared to the consensus estimate of $102.06 million. During the same quarter in the prior year, the firm earned $0.09 earnings per share. The company’s revenue for the quarter was up 27.0% compared to the same quarter last year. As a group, research analysts predict that Cellebrite DI will post 0.32 EPS for the current year.
Institutional Trading of Cellebrite DI
A number of hedge funds have recently added to or reduced their stakes in the business. Juncture Wealth Strategies LLC boosted its position in shares of Cellebrite DI by 0.8% in the fourth quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company’s stock worth $1,322,000 after acquiring an additional 505 shares during the last quarter. Strategic Advisors LLC raised its stake in Cellebrite DI by 3.4% during the fourth quarter. Strategic Advisors LLC now owns 29,082 shares of the company’s stock worth $641,000 after purchasing an additional 950 shares during the period. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Cellebrite DI by 59.6% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after purchasing an additional 1,017 shares during the last quarter. Steward Partners Investment Advisory LLC grew its stake in shares of Cellebrite DI by 12.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company’s stock valued at $299,000 after buying an additional 1,463 shares during the period. Finally, Tower View Wealth Management LLC increased its holdings in shares of Cellebrite DI by 1.2% during the 3rd quarter. Tower View Wealth Management LLC now owns 130,647 shares of the company’s stock worth $2,200,000 after buying an additional 1,500 shares during the last quarter. 45.88% of the stock is owned by institutional investors and hedge funds.
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
- Five stocks we like better than Cellebrite DI
- Canadian Penny Stocks: Can They Make You Rich?
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- How to Most Effectively Use the MarketBeat Earnings Screener
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.